MEHMET MERİÇ ÇOBAN, MEHMET NURİ YAKAR, MURAT KÜÇÜK, BİŞAR ERGÜN, MUAMMER ÇELİK, BEGÜM ERGAN, ERDEM YAKA, NECATİ GÖKMEN
Thoracic Research and Practice - 2022;23(2):185-191
Coronavirus disease 2019 is a novel viral infection that has caused a pandemic globally. Many kinds of vaccine development studies were conducted to prevent the spread and deaths. The CoronaVac is the most commonly used vaccine in Turkey. Phase 3 trials from various countries revealed that CoronaVac efficacy ranged from 50.7% to 91.25% but increased in moderate or severe cases to 100%. Additionally, it was remarkable owing to high seroconversion rates achieving up to 100%. After the vaccine campaign began in Turkey, critically ill patients continued to admit to our center’s intensive care unit though they had been vaccinated with 2 doses of CoronaVac. The clinical course of these patients revealed that they are still at high risk of severe disease and death. Therefore, we aimed to share these patients’ clinical characteristics and disease course, laboratory, and radiologic data.
